Ms. Hamill brings extensive experience and
proven leadership focused on commercial growth and shareholder
value
DUBLIN, July 25,
2024 /PRNewswire/ -- Jazz Pharmaceuticals
plc (Nasdaq: JAZZ) today announced the election of a new
independent director, Laura Hamill, to its Board of
Directors. Ms. Hamill, a 35-year veteran of the pharmaceutical
industry brings broad executive leadership and global commercial
operations expertise to the company's Board. Ms.
Hamill's election follows the appointment of Patrick Kennedy earlier this year and reflects
Jazz's continued focus on Board renewal. At the Annual General
meeting held today, shareholders not only elected Ms. Hamill and
Mr. Kennedy but also re-elected Kenneth
O'Keefe and Mark Smith to an
additional term.
"We are delighted to welcome Laura to the Board,"
said Bruce Cozadd, chairperson and CEO, Jazz
Pharmaceuticals. "Her extensive commercial and industry experience
and well-established track record with dynamic, multi-national
companies is exceptionally aligned with Jazz's focus on creating
value for shareholders. I feel certain Laura's expertise will
complement the capabilities of the existing Jazz Board as we aim to
transform the lives of patients and their families."
Ms. Hamill most recently held the position of Executive Vice
President, Worldwide Commercial Operations, for Gilead Sciences,
Inc. from 2018 to 2019. From 2002 to 2018, Ms. Hamill served in
various executive management positions at Amgen Inc., including
Senior Vice President, U.S. Commercial Operations, Senior Vice
President, Intercontinental Region, overseeing business operations
of 26 countries worldwide, Vice President, U.S. Corporate Accounts
and Reimbursement, Vice President, International Marketing and
Business Operations in Zug, Switzerland. Ms. Hamill currently serves on
the board of directors of Y-mAbs Therapeutics Inc., BB Biotech and
Unchained Labs, a privately held company.
"I am impressed by the global talent in the organization driving
the strength of Jazz's business," said Ms. Hamill. "I look
forward to the opportunity to work alongside my Board colleagues
and the company's management to help guide the company's future
growth in order to deliver sustained value to our shareholders and
meaningful impact for patients."
As previously disclosed and effective today, Peter Gray and Catherine
Sohn, Pharm.D., have retired from the Jazz Board, which now
will be comprised of twelve directors, five of whom have been
appointed in the past five years.
"I want to thank Cathy and Peter for their outstanding service
and dedication to Jazz," Mr. Cozadd added. "They both
have been valued members of the Jazz Board and instrumental in our
transformation and continued growth. We have been grateful for
their commitment and wish them well as they transition off the
Board."
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc
(Nasdaq: JAZZ) is a global biopharma company whose purpose is to
innovate to transform the lives of patients and their families. We
are dedicated to developing life-changing medicines for people with
serious diseases—often with limited or no therapeutic options. We
have a diverse portfolio of marketed medicines, including leading
therapies for sleep disorders and epilepsy, and a growing portfolio
of cancer treatments. Our patient-focused and science-driven
approach powers pioneering research and development advancements
across our robust pipeline of innovative therapeutics in oncology
and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development
laboratories, manufacturing facilities and employees in multiple
countries committed to serving patients worldwide. Please visit
www.jazzpharmaceuticals.com for more information.
Contacts:
Jazz Media Contact:
Kristin
Bhavnani
Head of Global Strategic Brand Engagement
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948
Jazz Investor Contact:
Andrea
N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
investorinfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717
View original content to download
multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-shareholders-elect-laura-hamill-to-the-companys-board-of-directors-at-annual-general-meeting-302206714.html
SOURCE Jazz Pharmaceuticals plc